메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류
인문학
인문학 일반 역사학 철학 종교학 어문학 기타 인문학
사회과학
사회과학 일반 경영학 관광학 교육학 군사학 문헌정보학 법학 사회학 신문방송학 심리과학 정치외교학 지리학 행정학 경제학 무역학 인류학 기타 사회과학
자연과학
자연과학 일반 물리학 생물학 생활과학 수학·통계학 천문학 지구과학 화학 기타 자연과학
공학
공학 일반 건축공학 기계공학 산업공학 재료·에너지공학 전기전자공학 조선해양공학 화학공학 컴퓨터학 기타공학
의약학
의학 일반 간호학 수의학 약학 한의학 기초의학 임상의학 기타 의약학
농수해양학
농수해양학 일반 농학 수산학 식품과학 임학 축산학 해상운송학 기타 농수해양학
예술체육학
예술 일반 디자인 미술 미용 사진 음악학 의상 체육 공연매체예술 기타 예술체육학
복합학
학제간연구 과학기술학 뇌인지과학 기술정책 기타 복합학

ENG

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Ghareeb Doaa A. (Alexandria University Egypt) Saleh Samar R. (Alexandria University Egypt) Seadawy Mohamed G. (Chemical Warfare Department MCL Almaza Egypt) Nofal Mohammed S. (Pharmaceutical and Fermentation Industries Development Centre (PFIDC) Egypt) Abdulmalek Shaymaa A. (Alexandria University Egypt) Hassan Salma. F. (Pharmaceutical and Fermentation Industries Development Centre (PFIDC) Egypt) Khedr Shaimaa M. (Pharmaceutical and Fermentation Industries Development Centre (PFIDC) Egypt) AbdElwahab Miral G. (Pharmaceutical and Fermentation Industry Development Center Egypt) Sobhy Ahmed A. (Alexandria University Egypt) Abdel-Hamid Ali saber Ali (Pharmaceutical and Fermentation Industry Development Center Egypt) Yassin Abdelrahman Mohamed (Pharmaceutical and Fermentation Industry Development Center Egypt) Elmoneam Alshimaa A. Abd (Alexandria University Egypt) Masoud Aliaa A. (Alexandria University Egypt) Kaddah Mohamed M. Y. (Pharmaceutical and Fermentation Industries Development Centre (PFIDC) Egypt) El-Zahaby Sally A. (Pharos University in Alexandria Egypt) Al-mahallawi Abdulaziz Mohsen (Cairo University Egypt) El-Gharbawy Alaa M. (Pharmaceutical and Fermentation Industry Development Center Egypt) Zaki Ahmed (Pharmaceutical and Fermentation Industry Development Center Egypt) Seif Inas K. (Alexandria University Egypt) Kenawy Marwa Y. (Advanced Technology and New Materials Research Institute (ATNMRI) Egypt) Amin Magdy (Military Medical Services Egypt) Amer Khaled (Egypt Center for Research and Regenerative Medicine Egypt) El Demellawy Maha Adel (Pharmaceutical and Fermentation Industry Development Center Egypt)
저널정보
한국약제학회 Journal of Pharmaceutical Investigation Journal of Pharmaceutical Investigation 제51권 제6호
발행연도
2021.11
수록면
735 - 757 (23page)
DOI
10.1007/s40005-021-00544-w

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Purpose A novel coronavirus (COVID-19) that has not been previously identified in humans and has no specific treatment has recently spread. Treatment trials using antiviral and immune-modulating drugs such as hydroxychloroquine (HCQ) were used to control this viral outbreak however several side effects have emerged. Berberine (BER) is an alkaloid that has been reported to reveal some pharmacological properties including antioxidant and antimicrobial activities. Additionally, Zinc oxide nanoparticles (ZnO-NPs) possess potent antioxidant and anti-inflammatory properties. Therefore, this study was undertaken to estimate the efficiency of both BER and synthetic ZnO/BER complex as an anti-COVID-19 therapy. Methods First, the ZnO/BER complex was prepared by the facile mixing method. Then in vitro studies on the two compounds were conducted including VeroE6 toxicity, anti-COVID-19 activity, determination of inhibitory activity towards papain-like proteinase (PL pro) and spike protein- and receptor- binding domain (RBD) as well as assessment of drug toxicity on RBCs. Results The results showed that ZnO/BER complex acts as an anti-COVID-19 by inhibiting spike protein binding with angiotensin-converting enzyme II (ACE II), PL pro activity, spike protein and E protein levels, and expression of both E-gene and RNA dependent RNA polymerase (RdRp) at a concentration lower than that of BER or ZnO-NPs alone. Furthermore, ZnO/BER complex had antioxidant and antimicrobial properties where it prevents the auto oxidation of 2,2-Diphenyl- 1-picrylhydrazyl (DPPH) and the culture of lower respiratory system bacteria that affected Covid 19 patients. The ZnO/BER complex prevented as well the HCQ cytotoxic effect on both RBC and WBC (in vitro) and hepatotoxicity, nephrotoxicity and anemia that occurred after HCQ long administration in vivo. Conclusion The ZnO/BER complex can be accounted as promising anti-COVID 19 candidate because it inhibited the virus entry, replication, and assembly. Furthermore, it could be used to treat a second bacterial infection that took place in hospitalized COVID 19 patients. Moreover, ZnO/BER complex was found to eliminate the toxicity of long-term administration of HCQ in vivo.
#COVID-19 #Papain-like proteinase #Spike protein RBD #Molecular docking analysis #ACE2 #Vero E6 toxicity #Berberine #ZnO nanoparticles

목차

등록된 정보가 없습니다.

참고문헌 (66)

참고문헌 신청
Abd El-Salam M / 2015 / Hepatoprotective properties and biotransformation of berberine and berberrubine by cell suspension cultures of Dodonaea viscosa and Ocimum basilicum / S Afr J Bot 97:191~195 google schola Aditya A / 2019 / ZnO Nanoparticles Modified with an Amphipathic Peptide Show Improved Photoprotection in Skin / ACS Appl Mater Interfaces 11:56~72 google schola Agency EM / COVID-19: chloroquine and اydroxychloroquine only be used in clinical trials or emergency use programmes google schola Al-Taie A / 2020 / Supplementary medicines and antioxidants in viral infections: a review of proposed effects for COVID-19 / Biomed Biotechnol Res J 4:19~24 google schola Barnabas RV / 2020 / Hydroxychloroquine as postexposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 infection / Ann Internal Med google schola

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0